论文部分内容阅读
乳腺癌作为女性最常见的恶性肿瘤之一,发病率正呈逐年上升趋势。全球每13分钟就有一人死于乳腺癌,并随着发病的不断增加,死亡率也在明显上升。乳腺癌已经在女性恶性肿瘤发病率中占第一位,成为威胁女性健康的“头号杀手”。这其中,大部分的乳腺癌类型均为HER-2+。许多的研究证明如果前期对HER-2过度表达的肿瘤应用针对HER-2的免疫疗法可以有效的控制肿瘤的发展。因此,建立体内的免疫应答可以控制过度表达HER-2的乳腺肿瘤病人的病情发展。随着曲妥珠单抗的产生和投入使用,启发人们发现更广阔的空间去构建针对HER-2的免疫应答的疫苗,从而使抗肿瘤的免疫作用更稳定更强大并且不会产生免疫耐受,进而防止肿瘤复发。因为现在针对HER-2产生的免疫耐受已经制约了肿瘤疫苗的发展,因此现在的研究热点是如何打破免疫耐受更好地发挥抗肿瘤的免疫作用。在这篇文章里,我们将着重介绍模拟HER-2的抗独特型单克隆抗体的应用。
As one of the most common malignant tumors in women, the incidence of breast cancer is increasing year by year. One person dies of breast cancer every 13 minutes globally and the mortality rate rises significantly as the disease continues to increase. Breast cancer has the highest incidence of malignant tumors in women, becoming “the number one killer” threatening the health of women. Among them, most of the breast cancer types are HER-2 +. Numerous studies have demonstrated that the use of immunotherapy against HER-2 in early HER-2 overexpression tumors can effectively control the development of tumors. Therefore, establishing an in vivo immune response can control the progression of breast cancer patients overexpressing HER-2. With the emergence and introduction of trastuzumab, people are encouraged to find more space to construct vaccines against the immune response to HER-2, making antitumor immunity more stable and powerful and not immune tolerant , Thereby preventing tumor recurrence. Because now the immune tolerance against HER-2 has restricted the development of tumor vaccines, the current research hotspot is how to break the immune tolerance to better exert anti-tumor immune function. In this article, we highlight the use of anti-idiotypic monoclonal antibodies that mimic HER-2.